Mechanisms of Allergen-Specific Immunotherapy: T-Regulatory Cells and More

Immunology and Allergy Clinics of North America

Volumn 26, Issue 2, 2006, Pages 207-231

  Verhagen, Johan ^a   Blaser, Kurt ^a   Akdis, Cezmi A ^a   Akdis, Mübeccel ^a  

^a SWISS INSTITUTE OF ALLERGY AND ASTHMA RESEARCH SIAF   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; ANTIBODY; ANTIGEN; ANTIHISTAMINIC AGENT; ANTITOXIN; AUTOANTIGEN; BACTERIAL ANTIGEN; BEE VENOM; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CASPASE; COLECALCIFEROL; CORTICOSTEROID; CYTOKINE; DEATH RECEPTOR; DEXAMETHASONE; FOOD ANTIGEN; GRASS POLLEN EXTRACT; HISTAMINE H2 RECEPTOR; IMMUNOGLOBULIN G; INTERLEUKIN 10; INTERLEUKIN 2; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LIPOPOLYSACCHARIDE; TERFENADINE; TRANSFORMING GROWTH FACTOR BETA; TUBERCULIN;

ADOPTIVE IMMUNOTHERAPY; ALLERGIC ASTHMA; ALLERGIC CONJUNCTIVITIS; ALLERGIC RHINITIS; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ATOPY; B LYMPHOCYTE ACTIVATION; BASOPHIL; BEE STING; CD4+ CD25+ T LYMPHOCYTE; CELL REGENERATION; CELL STIMULATION; CELL SURVIVAL; CELL TYPE; CELLULAR IMMUNITY; CLINICAL TRIAL; CLONAL ANERGY; CYTOKINE PRODUCTION; EFFECTOR CELL; EMBRYO DEVELOPMENT; ENVIRONMENTAL FACTOR; EOSINOPHIL; HAY FEVER; HEREDITY; HOUSE DUST ALLERGY; HUMAN; HYPERSENSITIVITY; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; INFLAMMATION; INFLAMMATORY CELL; INNATE IMMUNITY; LYMPHOCYTE CLONE; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE HOMING; LYMPHOID CELL; MAST CELL; MEASLES VIRUS; MEDIATOR RELEASE; MEMORY T LYMPHOCYTE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; SKIN ALLOGRAFT; T LYMPHOCYTE ACTIVATION; TARGET CELL; TH1 CELL; TH2 CELL; TUBERCULIN TEST;

ALLERGENS; DESENSITIZATION, IMMUNOLOGIC; HUMANS; HYPERSENSITIVITY; T-LYMPHOCYTES, REGULATORY;

EID: 33646410154     PISSN: 08898561     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.iac.2006.02.008     Document Type: Review

References (180)

1. Billingham R.E., Brent L., and Medawar P.B. Actively acquired tolerance of foreign cells. Nature 172 (1953) 603-606
2. Burnet F. The Nobel Lectures in Immunology. The Nobel Prize for Physiology or Medicine, 1960. Immunologic recognition of self. Scand J Immunol 33 (1991) 3-13
3. Burnet F.M. The production of antibodies (1949), Macmillan, Melbourne
4. Pirquet V. Das Verhalten der kutaanen Tuberkülin-reaktion wahrend der Masern. Munch Med Wochenschr 34 (1908) 1297-1300
5. Nossal G.J., and Pike B.L. Clonal anergy: persistence in tolerant mice of antigen-binding B lymphocytes incapable of responding to antigen or mitogen. Proc Natl Acad Sci USA 77 (1980) 1602-1606
6. Lamb J.R., Skidmore B.J., Green N., et al. Induction of tolerance in influenza virus-immune T lymphocyte clones with synthetic peptides of influenza hemagglutinin. J Exp Med 157 (1983) 1434-1447
7. Dhein J., Walczak H., Bäumler C., et al. Autocrine T-cell suicide mediated by APO-1(Fas/CD95). Nature 373 (1995) 438-441
8. Brunner T., Mogil R.J., LaFace D., et al. Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas. Nature 373 (1995) 441-444
9. Akdis C.A., Akdis M., Trautmann A., et al. Immune regulation in atopic dermatitis. Curr Opin Immunol 12 (2000) 641-646
10. Akdis C.A., Blaser K., and Akdis M. Apoptosis in tissue inflammation and allergic disease. Curr Opin Immunol 16 (2004) 717-723
11. + T cells respond to superantigen and contribute to eosinophilia and IgE production in atopic dermatitis. J Immunol 163 (1999) 466-475
12. Abernathy-Carver K.J., Sampson H.A., Picker L.J., et al. Milk-induced eczema is associated with the expansion of T cells expressing cutaneous lymphocyte antigen. J Clin Invest 95 (1995) 913-918
13. Klunker S., Trautmann A., Akdis M., et al. A second step of chemotaxis after transendothelial migration: keratinocytes undergoing apoptosis release IP-10, Mig and iTac for T cell chemotaxis towards epidermis in atopic dermatitis. J Immunol 171 (2003) 1078-1084
14. Luster A.D. The role of chemokines in linking innate and adaptive immunity. Curr Opin Immunol 14 (2002) 129-135
15. Gutierrez-Ramos J.C., Lloyd C., Kapsenberg M.L., et al. Non-redundant functional groups of chemokines operate in a coordinate manner during the inflammatory response in the lung. Immunol Rev 177 (2000) 31-42
16. Akdis M., Trautmann A., Klunker S., et al. T helper (Th) 2 predominance in atopic diseases is due to preferential apoptosis of circulating memory/effector Th1 cells. FASEB J 17 (2003) 1026-1035
17. Simon H.-U., and Blaser K. Inhibition of programmed eosinophil death: a key pathogenic event for eosinophilia. Immunol Today 16 (1995) 53-55
18. Whittaker L., Niu N., Temann U.A., et al. Interleukin-13 mediates a fundamental pathway for airway epithelial mucus induced by CD4 T cells and interleukin-9. Am J Respir Cell Mol Biol 27 (2002) 593-602
19. Trautmann A., Akdis M., Kleemann D., et al. T cell-mediated Fas-induced keratinocyte apoptosis plays a key pathogenetic role in eczematous dermatitis. J Clin Invest 106 (2000) 25-35
20. Trautmann A., Schmid-Grendelmeier P., Krüger K., et al. T cells and eosinophils cooperate in the induction of bronchial epithelial apoptosis in asthma. J Allergy Clin Immunol 109 (2002) 329-337
21. Trautmann A., Akdis M., Brocker E.B., et al. New insights into the role of T cells in atopic dermatitis and allergic contact dermatitis. Trends Immunol 22 (2001) 530-532
22. Trautmann A., Akdis M., Schmid-Grendelmeier P., et al. Targeting keratinocyte apoptosis in the treatment of atopic dermatitis and allergic contact dermatitis. J Allergy Clin Immunol 108 (2001) 839-846
23. Romagnani S. Lymphokine production by human T cells in disease states. Annu Rev Immunol 12 (1994) 227-257
24. Mosmann T.R., and Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today 17 (1996) 142-146
25. Rincon M., Anguita J., Nakamura T., et al. Interleukin (IL)-6 directs the differentiation of IL-4-producing CD4 + T cells. J Exp Med 185 (1997) 461-469
26. Corry D.B. IL-13 in allergy: home at last. Curr Opin Immunol 11 (1999) 610-614
27. Yssel H., and Groux H. Characterization of T cell subpopulations involved in the pathogenesis of asthma and allergic diseases. Int Arch Allergy Immunol 121 (2000) 10-18
28. El Biaze M., Boniface S., Koscher V., et al. T cell activation, from atopy to asthma: more a paradox than a paradigm. Allergy 58 (2003) 844-853
29. Chen Y., Kuchroo V.K., Inobe J., et al. Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. Science 265 (1994) 1237-1240
30. low CD4 + T cells are important for the balance between protective and pathogenic cell- mediated immunity. J Exp Med 179 (1994) 589-600
31. Groux H., O'Garra A., Bigler M., et al. CD4 + T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 389 (1997) 737-742
32. Akdis C.A., Blesken T., Akdis M., et al. Role of IL-10 in specific immunotherapy. J Clin Invest 102 (1998) 98-106
33. Taams L.S., Smith J., Rustin M.H., et al. Human anergic/suppressive CD4(+)CD25(+) T cells: a highly differentiated and apoptosis-prone population. Eur J Immunol 31 (2001) 1122-1131
34. Jonuleit H., Schmitt E., Schuler G., et al. Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J Exp Med 192 (2000) 1213-1222
35. Cottrez F., Hurst S.D., Coffman R.L., et al. T regulatory cells 1 inhibit a Th2-specific response in vivo. J Immunol 165 (2000) 4848-4853
36. Jutel M., Akdis M., Budak F., et al. IL-10 and TGF-β cooperate in regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy. Eur J Immunol 33 (2003) 1205-1214
37. Bousquet J. Global initiative for asthma (GINA) and its objectives. Clin Exp Allergy 30 Suppl 1 (2000) 2-5
38. Jutel M., Watanabe T., Klunker S., et al. Histamine regulates T-cell and antibody responses by differential expression of H1 and H2 receptors. Nature 413 (2001) 420-425
39. Holgate S.T. Asthma: more than an inflammatory disease. Curr Opin Allergy Clin Immunol 2 (2002) 27-29
40. Kussebi F., Karamloo F., Akdis M., et al. Advances in immunological treatment of allergy. Curr Med Chem 2 (2003) 297-308
41. Müller U.R., and Mosbech H. Position paper: Immunotherapy with hymenoptera venoms. Allergy 48 (1993) 36-46
42. Bousquet J., Lockey R., Malling H.J., et al. Allergen immunotherapy: therapeutic vaccines for allergic diseases. World Health Organization. American academy of Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol 81 (1998) 401-405
43. Walker S.M., Varney V.A., Gaga M., et al. Grass pollen immunotherapy: efficacy and safety during a 4-year follow- up study. Allergy 50 (1995) 405-413
44. Varney V.A., Gaga M., Frew A.J., et al. Usefulness of immunotherapy in patients with severe summer hay fever uncontrolled by antiallergic drugs. BMJ 302 (1991) 265-269
45. Durham S.R., Walker S.M., Varga E.M., et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 341 (1999) 468-475
46. Noon L. Prophylactic inoculation against hay fever. Lancet 1 (1911) 1572-1573
47. Cooke R., Banard J.H., Hebald S., et al. Serological evidence of immunity with coexisting sensitization in a type of human allergy (hay fever). J Exp Med 62 (1935) 733-751
48. Lichtenstein L., Norman P.S., Winkenwerder W.L., et al. In vitro studies of human ragweed allergy: changes in cellular and humoral activity associated with specific desensitization. J Clin Invest 45 (1966) 1126-1136
49. Akdis C.A., Akdis M., Blesken T., et al. Epitope-specific T cell tolerance to phospholipase A2 in bee venom immunotherapy and recovery by IL-2 and IL-15 in vitro. J Clin Invest 98 (1996) 1676-1683
50. Durham S.R., and Till S.J. Immunological changes associated with allergen immunotherapy. J Allergy Clin Immunol 102 (1998) 157-164
51. Rolland J.M., Douglass J., and O'Hehir R.E. Allergen immunotherapy: current and new therapeutic strategies. Expert Opin Investig Drugs 9 (2000) 515-527
52. Akdis C.A., and Blaser K. IL-10-induced anergy in peripheral T cell and reactivation by microenvironmental cytokines: two key steps in specific immunotherapy. FASEB J 13 (1999) 603-609
53. Ebner C. Immunological mechanisms operative in allergen-specific immunotherapy. Int Arch Allergy Immunol 119 (1999) 1-5
54. Akdis C.A., and Blaser K. Mechanisms of allergen-specific immunotherapy. Allergy 55 (2000) 522-530
55. Flicker S., Steinberger P., Norderhaug L., et al. Conversion of grass pollen allergen-specific human IgE into a protective IgG(1) antibody. Eur J Immunol 32 (2002) 2156-2162
56. Wetterwald A., Skvaril F., Muller U., et al. Isotypic and idiotypic characterization of anti-bee venom phospholipase A2 antibodies. Int Arch Allergy Appl Immunol 77 (1985) 195-197
57. van Neerven R.J., Wikborg T., Lund G., et al. Blocking antibodies induced by specific allergy vaccination prevent the activation of CD4 + T cells by inhibiting serum-IgE-facilitated allergen presentation. J Immunol 163 (1999) 2944-2952
58. Rocklin R.E., Sheffer A., Greineder D.K., et al. Generation of antigen-specific suppressor cells during allergy desensitization. N Engl J Med 302 (1980) 1213-1219
59. Creticos P.S., Adkinson Jr. N.F., Kagey-Sobotka A., et al. Nasal challenge with ragweed pollen in hay fever patients. Effect of immunotherapy. J Clin Invest 76 (1985) 2247-2253
60. Rak S., Lowhagen O., and Venge P. The effect of immunotherapy on bronchial hyperresponsiveness and eosinophil cationic protein in pollen-allergic patients. J Allergy Clin Immunol 82 (1988) 470-480
61. Otsuka H., Mezawa A., Ohnishi M., et al. Changes in nasal metachromatic cells during allergen immunotherapy. Clin Exp Allergy 21 (1991) 115-119
62. Jutel M., Pichler W.J., Skrbic D., et al. Bee venom immunotherapy results in decrease of IL-4 and IL-5 and increase of IFN-gamma secretion in specific allergen-stimulated T cell cultures. J Immunol 154 (1995) 4187-4194
63. Secrist H., Chelen C.J., Wen Y., et al. Allergen immunotherapy decreases interleukin 4 production in CD4 + T cells from allergic individuals. J Exp Med 178 (1993) 2123-2130
64. Bellinghausen I., Metz G., Enk A.H., et al. Insect venom immunotherapy induces interleukin-10 production and a Th2- to-Th1 shift, and changes surface marker expression in venom-allergic subjects. Eur J Immunol 27 (1997) 1131-1139
65. Varney V.A., Hamid Q.A., Gaga M., et al. Influence of grass pollen immunotherapy on cellular infiltration and cytokine mRNA expression during allergen-induced late-phase cutaneous responses. J Clin Invest 92 (1993) 644-651
66. Varga E.M., Wachholz P., Nouri-Aria K.T., et al. T cells from human allergen-induced late asthmatic responses express IL-12 receptor beta 2 subunit mRNA and respond to IL-12 in vitro. J Immunol 165 (2000) 2877-2885
67. Hamid Q.A., Schotman E., Jacobson M.R., et al. Increases in IL-12 messenger RNA + cells accompany inhibition of allergen-induced late skin responses after successful grass pollen immunotherapy. J Allergy Clin Immunol 99 (1997) 254-260
68. Durham S.R., Ying S., Varney V.A., et al. Grass pollen immunotherapy inhibits allergen-induced infiltration of CD4 + T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferon-gamma. J Allergy Clin Immunol 97 (1996) 1356-1365
69. Wachholz P.A., Nouri-Aria K.T., Wilson D.R., et al. Grass pollen immunotherapy for hayfever is associated with increases in local nasal but not peripheral Th1:Th2 cytokine ratios. Immunology 105 (2002) 56-62
70. Akdis M., Verhagen J., Taylor A., et al. Immune responses in healthy and allergic individuals are characterized by a fine balance between allergen-specific T regulatory 1 and T helper 2 cells. J Exp Med 199 (2004) 1567-1575
71. Oral H.B., Kotenko S.V., Yilmaz M., et al. Regulation of T cells and cytokines by the interleukin-10 (IL-10)-family cytokines IL-19, IL-20, IL-22, IL-24 andIL-26. Eur J Immunol 36 (2006) 380-388
72. Borish L., Aarons A., Rumbyrt J., et al. Interleukin-10 regulation in normal subjects and patients with asthma. J Allergy Clin Immunol 97 (1996) 1288-1296
73. Koning H., Neijens H.J., Baert M.R., et al. T cells subsets and cytokines in allergic and non-allergic children. II. Analysis and IL-5 and IL-10 mRNA expression and protein production. Cytokine 9 (1997) 427-436
74. Vignola A.M., Chanez P., Chiappara G., et al. Transforming growth factor-beta expression in mucosal biopsies in asthma and chronic bronchitis. Am J Respir Crit Care Med 156 (1997) 591-599
75. Hellings P.W., Vandenberghe P., Kasran A., et al. Blockade of CTLA-4 enhances allergic sensitization and eosinophilic airway inflammation in genetically predisposed mice. Eur J Immunol 32 (2002) 585-594
76. Punnonen J., De Waal Malefyt R., Van Vlasselaer P., et al. IL-10 and viral IL-10 prevent IL-4-indiced IgE synthesis by inhibiting the accessory cell function of monocytes. J Immunol 151 (1993) 1280-1289
77. Sonoda E., Matsumoto R., Hitoshi Y., et al. Transforming growth factor beta induces IgA production and acts additively with interleukin 5 for IgA production. J Exp Med 170 (1989) 1415-1420
78. Flicker S., and Valenta R. Renaissance of the blocking antibody concept in type I allergy. Int Arch Allergy Immunol 132 (2003) 13-24
79. Wachholz P.A., and Durham S.R. Mechanisms of immunotherapy: IgG revisited. Curr Opin Allergy Clin Immunol 4 (2004) 313-318
80. Golden D.B., Meyers D.A., Kagey-Sobotka A., et al. Clinical relevance of the venom-specific immunoglobulin G antibody level during immunotherapy. J Allergy Clin Immunol 69 (1982) 489-493
81. Müller U.R., Helbling A., and Bischof M. Predictive value of venom-specific IgE, IgG and IgG subclass antibodies in patients on immunotherapy with honey bee venom. Allergy 44 (1989) 412-418
82. Nouri-Aria K.T., Wachholz P.A., Francis J.N., et al. Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity. J Immunol 172 (2004) 3252-3259
83. Jutel M., Jaeger L., Suck R., et al. Allergen-specific immunotherapy with recombinant grass pollen allergens. J Allergy Clin Immunol 116 (2005) 608-613
84. Rossi R.E., and Monasterolo G. Evaluation of recombinant and native timothy pollen (rPhl p 1, 2, 5, 6, 7, 11, 12 and nPhl p 4)- specific IgG4 antibodies induced by subcutaneous immunotherapy with timothy pollen extract in allergic patients. Int Arch Allergy Immunol 135 (2004) 44-53
85. Walker C., Virchow J.-C., Bruijnzeel P.L.B., et al. T cell subsets and their soluble products regulate eosinophilia in allergic and nonallergic asthma. J Immunol 146 (1991) 1829-1835
86. Schleimer R.P., Derse C.P., Friedman B., et al. Regulation of human basophil mediator release by cytokines. I. Interaction with anti-inflammatory steroids. J Immunol 143 (1989) 1310-1327
87. Marshall J.S., Leal-Berumen I., Nielsen L., et al. Interleukin (IL)-10 Inhibits long-term IL-6 production but not preformed mediator release from rat peritoneal mast cells. J Clin Invest 97 (1996) 1122-1128
88. Schandane L., Alonso-Vega C., Willems F., et al. B7/CD28-dependent IL-5 production by human resting T cells is inhibited by IL-10. J Immunol 152 (1994) 4368-4374
89. Ohkawara Y., Lim K.G., Glibetic M., et al. CD40 expression by human peripheral blood eosinophils. J Clin Invest 97 (1996) 1761-1766
90. Knechtle S.J., Hamawy M.M., Hu H., et al. Tolerance and near-tolerance strategies in monkeys and their application to human renal transplantation. Immunol Rev 183 (2001) 205-213
91. Chambers C.A. The expanding world of co-stimulation: the two-signal model revisited. Trends Immunol 22 (2001) 217-223
92. Schwartz R.H. Models of T cell anergy: is there a common molecular mechanism?. J Exp Med 184 (1996) 1-8
93. lck and ZAP-70 tyrosine kinase activities. J Immunol 159 (1997) 53-60
94. Hoyne G.F., O'Hehir R., Wraith D.C., et al. Inhibition of T cell and antibody responses to house dust mite allergen by inhalation of the dominant T cell epitope in naive and sensitized mice. J Exp Med 178 (1993) 1783-1788
95. Haczku A., Takeda K., Redai I., et al. Anti-CD86 (B7.2) treatment abolishes allergic airway hyperresponsiveness in mice. Am J Respir Crit Care Med 159 (1999) 1638-1643
96. Van Oosterhout A.J., Hofstra C.L., Shields R., et al. Murine CTLA4-IgG treatment inhibits airway eosinophilia and hyperresponsiveness and attenuates IgE upregulation in a murine model of allergic asthma. Am J Respir Cell Mol Biol 17 (1997) 386-392
97. Van Neerven R.J., Van de Pol M.M., Van der Zee J.S., et al. Requirement of CD28-CD86 costimulation for allergen-specific T cell proliferation and cytokine expression. Clin Exp Allergy 28 (1998) 808-816
98. Gonzalo J.A., Tian J., Delaney T., et al. ICOS is critical for T helper cell-mediated lung mucosal inflammatory responses. Nat Immunol 2 (2001) 597-604
99. Dong C., Juedes A.E., Temann U.A., et al. ICOS co-stimulatory receptor is essential for T-cell activation and function. Nature 409 (2001) 97-101
100. Akdis C.A., Joss A., Akdis M., et al. A molecular basis for T cell suppression by IL-10: CD28-associated IL-10 receptor inhibits CD28 tyrosine phosphorylation and phosphatidylinositol 3-kinase binding. FASEB J 14 (2000) 1666-1669
101. Joss A., Akdis M., Faith A., et al. IL-10 directly acts on T cells by specifically altering the CD28 co-stimulation pathway. Eur J Immunol 30 (2000) 1683-1690
102. Prasad K.V.S., Cai Y.-C., Raab M., et al. T-cell antigen CD28 interacts with the lipid kinase phosphatidylinositol 3-kinase by a cytoplasmic Tyr(P)-Met-Xaa-Met motif. Proc Natl Acad Sci USA 91 (1994) 2834-2838
103. Levings M.K., Sangregorio R., Galbiati F., et al. IFN-alpha and IL-10 induce the differentiation of human type 1 T regulatory cells. J Immunol 166 (2001) 5530-5539
104. Bacchetta R., Sartirana C., Levings M.K., et al. Growth and expansion of human T regulatory type 1 cells are independent from TCR activation but require exogenous cytokines. Eur J Immunol 32 (2002) 2237-2245
105. Roncarolo M.G., Bacchetta R., Bordignon C., et al. Type 1 T regulatory cells. Immunol Rev 182 (2001) 68-79
106. 2 induces specific T cell anergy in bee sting allergic patients. J Allergy Clin Immunol 101 (1998) 747-754
107. Barrat F.J., Cua D.J., Boonstra A., et al. In vitro generation of interleukin 10-producing regulatory CD4(+) T cells is induced by immunosuppressive drugs and inhibited by T helper type 1 (Th1)- and Th2-inducing cytokines. J Exp Med 195 (2002) 603-616
108. Nasser S.M., Ying S., Meng O., et al. Interleukin-10 levels increase in cutaneous biopsies of patients undergoing wasp venom immunotherapy. Eur J Immunol 31 (2001) 3704-3713
109. Chen Y., Inobe J., Kuchroo V.K., et al. Oral tolerance in myelin basic protein T-cell receptor transgenic mice: suppression of autoimmune encephalomyelitis and dose-dependent induction of regulatory cells. Proc Natl Acad Sci USA 93 (1996) 388-391
110. Sakaguchi S., Sakaguchi N., Asano M., et al. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 155 (1995) 1151-1164
111. Shevach E.M. CD4 + CD25 + suppressor T cells: more questions than answers. Nat Rev Immunol 2 (2002) 389-400
112. Wood K.J., and Sakaguchi S. Regulatory T cells in transplantation tolerance. Nat Rev Immunol 3 (2003) 199-210
113. Read S., and Powrie F. CD4(+) regulatory T cells. Curr Opin Immunol 13 (2001) 644-649
114. Hori S., Nomura T., and Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 299 (2003) 1057-1061
115. Read S., Mauze S., Asseman C., et al. CD38 + CD45RB(low) CD4 + T cells: a population of T cells with immune regulatory activities in vitro. Eur J Immunol 28 (1998) 3435-3447
116. Ke Y., and Kapp J.A. Oral antigen inhibits priming of CD8 + CTL, CD4 + T cells, and antibody responses while activating CD8 + suppressor T cells. J Immunol 156 (1996) 916-921
117. Weiner H.L. Oral tolerance for the treatment of autoimmune diseases. Annu Rev Med 48 (1997) 341-351
118. Ciubotariu R., Colovai A.I., Pennesi G., et al. Specific suppression of human CD4 + Th cell responses to pig MHC antigens by CD8 + CD28- regulatory T cells. J Immunol 161 (1998) 5193-5202
119. Suvas S., Kumaraguru U., Pack C.D., et al. CD4 + CD25 + T cells regulate virus-specific primary and memory CD8 + T cell responses. J Exp Med 198 (2003) 889-901
120. Strober S., Cheng L., Zeng D., et al. Double negative (CD4-CD8- alpha beta +) T cells which promote tolerance induction and regulate autoimmunity. Immunol Rev 149 (1996) 217-230
121. Zhang Z.X., Yang L., Young K.J., et al. Identification of a previously unknown antigen-specific regulatory T cell and its mechanism of suppression. Nat Med 6 (2000) 782-789
122. Hanninen A., and Harrison L.C. Gamma delta T cells as mediators of mucosal tolerance: the autoimmune diabetes model. Immunol Rev 173 (2000) 109-119
123. Seo N., Tokura Y., Takigawa M., et al. Depletion of IL-10- and TGF-beta-producing regulatory gamma delta T cells by administering a daunomycin-conjugated specific monoclonal antibody in early tumor lesions augments the activity of CTLs and NK cells. J Immunol 163 (1999) 242-249
124. Ke Y., Pearce K., Lake J.P., et al. Gamma delta T lymphocytes regulate the induction and maintenance of oral tolerance. J Immunol 158 (1997) 3610-3618
125. Seymour B.W., Gershwin L.J., and Coffman R.L. Aerosol-induced immunoglobulin (Ig)-E unresponsiveness to ovalbumin does not require CD8 + or T cell receptor (TCR)-gamma/delta + T cells or interferon (IFN)-gamma in a murine model of allergen sensitization. J Exp Med 187 (1998) 721-731
126. Mauri C., Gray D., Mushtaq N., et al. Prevention of arthritis by interleukin 10-producing B cells. J Exp Med 197 (2003) 489-501
127. Akbari O., DeKruyff R.H., and Umetsu D.T. Pulmonary dendritic cells producing IL-10 mediate tolerance induced by respiratory exposure to antigen. Nat Immunol 2 (2001) 725-731
128. Steinbrink K., Wolfl M., Jonuleit H., et al. Induction of tolerance by IL-10-treated dendritic cells. J Immunol 159 (1997) 4772-4780
129. Morganti-Kossmann M.C., Kossmann T., Brandes M.E., et al. Autocrine and paracrine regulation of astrocyte function by transforming growth factor-beta. J Neuroimmunol 39 (1992) 163-173
130. Kao J.Y., Gong Y., Chen C.M., et al. Tumor-derived TGF-beta reduces the efficacy of dendritic cell/tumor fusion vaccine. J Immunol 170 (2003) 3806-3811
131. Rivas J.M., and Ullrich S.E. Systemic suppression of delayed-type hypersensitivity by supernatants from UV-irradiated keratinocytes. An essential role for keratinocyte-derived IL-10. J Immunol 149 (1992) 3865-3871
132. Lidstrom C., Matthiesen L., Berg G., et al. Cytokine secretion patterns of NK cells and macrophages in early human pregnancy decidua and blood: implications for suppressor macrophages in decidua. Am J Reprod Immunol 50 (2003) 444-452
133. Dowdell K.C., Cua D.J., Kirtkman E., et al. NK cells regulate CD4 responses prior to antigen encounter. J Immunol 171 (2003) 234-239
134. Kitamura M., Suto T., Yokoo T., et al. Transforming growth factor-beta 1 is the predominant paracrine inhibitor of macrophage cytokine synthesis produced by glomerular mesangial cells. J Immunol 156 (1996) 2964-2971
135. Weiner H.L. Induction and mechanism of action of transforming growth factor-beta- secreting Th3 regulatory cells. Immunol Rev 182 (2001) 207-214
136. Jordan M.S., Riley M.P., von Boehmer H., et al. Anergy and suppression regulate CD4(+) T cell responses to a self peptide. Eur J Immunol 30 (2000) 136-144
137. Vermaelen K.Y., Carro-Muino I., Lambrecht B.N., et al. Specific migratory dendritic cells rapidly transport antigen from the airways to the thoracic lymph nodes. J Exp Med 193 (2001) 51-60
138. Lambrecht B.N., Pauwels R.A., and Fazekas De St Groth B. Induction of rapid T cell activation, division, and recirculation by intratracheal injection of dendritic cells in a TCR transgenic model. J Immunol 164 (2000) 2937-2946
139. de Heer H.J., Hammad H., Soullie T., et al. Essential role of lung plasmacytoid dendritic cells in preventing asthmatic reactions to harmless inhaled antigen. J Exp Med 200 (2004) 89-98
140. Peek E.J., Richards D.F., Faith A., et al. Interleukin-10-secreting "regulatory" T cells induced by glucocorticoids and beta2-agonists. Am J Respir Cell Mol Biol 33 (2005) 105-111
141. Karagiannidis C., Akdis M., Holopainen P., et al. Glucocorticoids upregulate FOXP3 expression and regulatory T cells in asthma. J Allergy Clin Immunol 114 (2004) 1425-1433
142. Qin S., Cobbold S.P., Pope H., et al. "Infectious" transplantation tolerance. Science 259 (1993) 974-977
143. Verhagen J., Akdis M., Traidl-Hoffmann C., et al. Absence of T-regulatory cell expression and function in atopic dermatitis skin. J Allergy Clin Immunol 117 (2006) 176-183
144. Thornton A.M., and Shevach E.M. CD4 + CD25 + immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med 188 (1998) 287-296
145. Nakamura K., Kitani A., and Strober W. Cell contact-dependent immunosuppression by CD4(+)CD25(+) regulatory T cells is mediated by cell surface-bound transforming growth factor beta. J Exp Med 194 (2001) 629-644
146. Levings M.K., Bachetta R., Schulz U., et al. The role of IL-10 and TGF-beta in the differentiation and effector function of T regulatory cells. Int Arch Allergy Appl Immunol 129 (2002) 263-276
147. Itoh M., Takahashi T., Sakaguchi N., et al. Thymus and autoimmunity: production of CD25 + CD4 + naturally anergic and suppressive T cells as a key function of the thymus in maintaining immunologic self-tolerance. J Immunol 162 (1999) 5317-5326
148. Fowell D., and Mason D. Evidence that the T cell repertoire of normal rats contains cells with the potential to cause diabetes. Characterization of the CD4 + T cell subset that inhibits this autoimmune potential. J Exp Med 177 (1993) 627-636
149. Asano M., Toda M., Sakaguchi N., et al. Autoimmune disease as a consequence of developmental abnormality of a T cell subpopulation. J Exp Med 184 (1996) 387-396
150. Annunziato F., Cosmi L., Liotta F., et al. Phenotype, localization, and mechanism of suppression of CD4 + CD25 + human thymocytes. J Exp Med 196 (2002) 379-387
151. Takahashi T., Tagami T., Yamazaki S., et al. Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med 192 (2000) 303-310
152. Read S., Malmstrom V., and Powrie F. Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation. J Exp Med 192 (2000) 295-302
153. Nishimura H., Nose M., Hiai H., et al. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 11 (1999) 141-151
154. Carter L., Fouser L.A., Jussif J., et al. PD-1:PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2. Eur J Immunol 32 (2002) 634-643
155. McHugh R.S., Whitters M.J., and Piccirillov C.A. CD4(+)CD25(+) immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor. Immunity 16 (2002) 311-323
156. Shimizu J., Yamazaki S., Takahashi T., et al. Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance. Nat Immunol 3 (2002) 135-142
157. Nocentini G., Giunchi L., Ronchetti S., et al. A new member of the tumor necrosis factor/nerve growth factor receptor family inhibits T cell receptor-induced apoptosis. Proc Natl Acad Sci USA 94 (1997) 6216-6221
158. Lehmann J., Huehn J., de la Rosa M., et al. Expression of the integrin alpha E beta 7 identifies unique subsets of CD25 + as well as CD25- regulatory T cells. Proc Natl Acad Sci USA 99 (2002) 13031-13036
159. Levings M.K., Sangregorio R., and Roncarolo M.G. Human CD25(+)CD4(+) T regulatory cells suppress naive and memory T cell proliferation and can be expanded in vitro without loss of function. J Exp Med 193 (2001) 1295-1302
160. Khattri R., Cox T., Yasayko S.A., et al. An essential role for Scurfin in CD4 + CD25 + T regulatory cells. Nat Immunol 4 (2003) 337-342
161. Fontenot J.D., Gavin M.A., and Rudensky A.Y. Foxp3 programs the development and function of CD4 + CD25 + regulatory T cells. Nat Immunol 4 (2003) 330-336
162. Kanangat S., Blair P., Reddy R., et al. Disease in the scurfy (sf) mouse is associated with overexpression of cytokine genes. Eur J Immunol 26 (1996) 161-165
163. Schubert L.A., Jeffrey E., Zhang Y., et al. Scurfin (FOXP3) acts as a repressor of transcription and regulates T cell activation. J Biol Chem 276 (2001) 37672-37679
164. Wildin R.S., Ramsdell F., Peake J., et al. X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy. Nat Genet 27 (2001) 18-20
165. Walker L.S., Chodos A., Eggena M., et al. Antigen-dependent proliferation of CD4 + CD25 + regulatory T cells in vivo. J Exp Med 198 (2003) 249-258
166. Sakaguchi S., and Sakaguchi N. Organ-specific autoimmune disease induced in mice by elimination of T cell subsets. V. Neonatal administration of cyclosporin A causes autoimmune disease. J Immunol 142 (1989) 471-480
167. Sakaguchi S., Sakaguchi N., Asano M., et al. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 155 (1995) 1151-1164
168. Powrie F., Mauze S., and Coffman R.L. CD4 + T-cells in the regulation of inflammatory responses in the intestine. Res Immunol 148 (1997) 576-581
169. Salomon B., Lenschow D.J., Rhee L., et al. B7/CD28 costimulation is essential for the homeostasis of the CD4 + CD25 + immunoregulatory T cells that control autoimmune diabetes. Immunity 12 (2000) 431-440
170. Mottet C., Uhlig H.H., and Powrie F. Cutting edge: cure of colitis by CD4 + CD25 + regulatory T cells. J Immunol 170 (2003) 3939-3943
171. Sutmuller R.P., van Duivenvoorde L.M., van Elsas A., et al. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med 194 (2001) 823-832
172. Shimizu J., Yamazaki S., and Sakaguchi S. Induction of tumor immunity by removing CD25 + CD4 + T cells: a common basis between tumor immunity and autoimmunity. J Immunol 163 (1999) 5211-5218
173. Jutel M., Watanabe T., Akdis M., et al. Immune regulation by histamine. Curr Opin Immunol 14 (2002) 735-740
174. Akdis C.A., and Blaser K. Histamine in the immune regulation of allergic inflammation. J Allergy Clin Immunol 112 (2003) 15-22
175. Del Valle J., and Gantz I. Novel insights into histamine H2 receptor biology. Am J Physiol 273 (1997) G987-G996
176. Mazzoni A., Young H.A., Spitzer J.H., et al. Histamine regulates cytokine production in maturing dendritic cells, resulting in altered T cell polarization. J Clin Invest 108 (2001) 1865-1873
177. Osna N., Elliott K., and Khan M.M. Regulation of interleukin-10 secretion by histamine in TH2 cells and splenocytes. Int Immunopharmacol 1 (2001) 85-96
178. Kunzmann S., Mantel P.-Y., Wohlfahrt J., et al. Histamine enhances TGF-beta1-mediated suppression of Th2 responses. FASEB J 17 (2003) 1089-1095
179. Müller U., Hari Y., and Berchtold E. Premedication with antihistamines may enhance efficacy of specific- allergen immunotherapy. J Allergy Clin Immunol 107 (2001) 81-86
180. Jutel M., Zak-Nejmark T., Wrzyyszcz M., et al. Histamine receptor expression on peripheral blood CD4 + lymphocytes is influenced by ultrarush bee venom immunotherapy. Allergy 52 Suppl 37 (1997) 88